Download or read book Pfizer and the Challenges of the Global Pharmaceutical Industry written by Axel Jörn and published by Anchor Academic Publishing. This book was released on 2016-07 with total page 33 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Case Study defines the global pharmaceutical industry and its „boundaries“, analyses the profitability/attractiveness of the global pharmaceutical industry by using M.E.Porters’ Five-Forces-Model and answers the questions what overall industry trends can be identified and how the profitability/attractiveness of the industry will change in the future. Furthermore, it explains and evaluates Pfizer’s new strategy and examines what Pfizer did in the recent years to maintain their profitability.
Download or read book Pfizer and the Challenges of the Global Pharmaceutical Industry written by Axel Jörn and published by Anchor Academic Publishing. This book was released on 2016-02-05 with total page 29 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Case Study defines the global pharmaceutical industry and its „boundaries“, analyses the profitability/attractiveness of the global pharmaceutical industry by using M.E.Porters’ Five-Forces-Model and answers the questions what overall industry trends can be identified and how the profitability/attractiveness of the industry will change in the future. Furthermore it explains and evaluates Pfizer’s new strategy and examines what Pfizer did in the recent years to maintain their profitability.
Download or read book Devalued and Distrusted written by John L. LaMattina and published by John Wiley & Sons. This book was released on 2012-12-10 with total page 173 pages. Available in PDF, EPUB and Kindle. Book excerpt: An expert's view on solving the challenges confronting today's pharmaceutical industry Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being. As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities. Starting with "4 Secrets that Drug Companies Don't Want You to Know," Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as: Why pharmaceutical R&D productivity has declined Where pharmaceutical companies need to invest their resources What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases How the pharmaceutical industry can regain public trust and resuscitate its image Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges. Get to know the author: Read an interview with John LaMattina or watch a video on ChemistryViews! Interview: John LaMattina: 30 Years in Pharma Video: Can the Pharmaceutical Industry Restory its Broken Image?
Download or read book Global Health Partnerships written by Mei-Ling Wang and published by Springer. This book was released on 2008-11-28 with total page 203 pages. Available in PDF, EPUB and Kindle. Book excerpt: An exploration into the current status and future growth of the global pharmaceutical industry and the changing needs of global health. It provides comprehensive coverage of the role of the global pharmaceutical industry in general, and the participation of BRICAs in specific, to address global health needs.
Download or read book The Global Pharmaceutical Industry in the 1990s written by Barrie G. James and published by . This book was released on 1990 with total page 116 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Global Pharmaceutical Industry written by Daniel Hoffman and published by Routledge. This book was released on 2020-07-06 with total page 95 pages. Available in PDF, EPUB and Kindle. Book excerpt: The pharmaceutical industry, long thought of as a recession-proof investment, now faces a day of reckoning. The reasons for this impending downfall are not hard to discern. The prices the industry charges for its prescription drugs have escalated at four to five times the cost-of-living increases during the past two decades and have reached a point where 30% of Americans must choose between filling a prescription, paying for housing, and buying food. This has brought about public pressure on governments around the world to control drug prices, yet the world’s twenty largest pharma companies realized 80% of their growth as a result of exorbitant price hikes. Pharma currently enjoys its extraordinary profitability by exploiting the world’s most vulnerable populations. Yet even their ability to increase prices in the face of falling demand does not satisfy their profit demands. The breadth and depth of pharma’s marketing transgressions exceed those of any other industry and have now reached a point where authorities around the world have found it necessary to take legal action against its violations. Drastic change is needed if the pharmaceutical industry can equitably advance the health of the world’s population and regain public esteem. This book illustrates the range and extent of pharma’s violations and addresses the actions that should be implemented in order to make the drug industry a more constructive, less venal part of contemporary society. It will be of interest to researchers, academics, practitioners, and students with an interest in the pharmaceutical industry, healthcare management, regulation, and bioethics.
Download or read book Pharma and Profits written by John L. LaMattina and published by John Wiley & Sons. This book was released on 2022-07-06 with total page 116 pages. Available in PDF, EPUB and Kindle. Book excerpt: High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis C mRNA vaccines and the race for a cure Why the government does not deserve a piece of Biopharma’s profits Paying for drugs whose ultimate value is unknown The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
Download or read book Innovation Growth A Case Study of Pfizer written by Miriam Mennen and published by GRIN Verlag. This book was released on 2010-03 with total page 29 pages. Available in PDF, EPUB and Kindle. Book excerpt: Essay from the year 2007 in the subject Business economics - Business Management, Corporate Governance, grade: 69% - B, University of Sunderland (Faculty of Business and Law), course: Innovation & Growth, language: English, abstract: Pfizer Inc. is taken as case study for an innovative company in the pharmaceutical sector. Firstly, the author will look at its mission statement in relation to its key stakeholders. Secondly, the company's overall strategy will be outlined regarding its positioning on the market as well the linkage to key theories which will be discussed and applied. The third part focuses on Pfizer's operational issues. Finally a comparison of the strategic performance and application of theories between Microsoft and Pfizer, both, two highly innovative companies, will be made. Pfizer, as the main case study, was chosen, because it can be defined as a highly innovative company, ranking globally the second by R&D expenditure on the DTI R&D scoreboard (see Appendix 1). However, according to the 'Business Week' the company ranks only on place 55 in the world's most innovative companies, with a margin growth of 1.8% and stock returns of 9.9% between 1995 till 2005. (Business Week, 2006) This provides the evidence that Pfizer is an innovative company.
Download or read book Global Pharmaceuticals written by Adriana Petryna and published by Duke University Press. This book was released on 2006-03-15 with total page 314 pages. Available in PDF, EPUB and Kindle. Book excerpt: DIVAnthropological study of the globalization of pharmaceuticals and its effects on local cultures, health, and economics./div
Download or read book Big Data for Big Pharma written by Malena Johannes and published by ibidem-Verlag / ibidem Press. This book was released on 2016-06-16 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt: Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation. Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry.
Download or read book Leading Pharmaceutical Innovation written by Oliver Gassmann and published by Springer Science & Business Media. This book was released on 2008-02-19 with total page 194 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Download or read book The Impact of the Merge of Pfizer and Mylan Pharmaceuticals written by Ty Branch and published by . This book was released on 2019 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt: First, in this deconstruction essay paper, the goal is to examine the acquisition and merger M&A of Pfizer Inc. (PFE) and Mylan, N.V. organizational relationships. Pfizer a famous global drug company known for their developing of product cures for erectile dysfunctions called 'Viagra' as well as, globally recognized for the magic 'blue pill' is one of the world's larger pharmaceutical firms in the world. Also, to focus on the economic model that will drive both Pfizer and Mylan's growth and investment in the organization's operations (internal growth). Next, the impact that this merger will have on the organization's size (external growth) that will be taken into consideration. Moreover, to deconstruct Mylan N.V. (MYL) global pharmaceutical company, specializing in the healthcare industry are they committed to raising the bar in manufacturing of high-quality medicine and will the combined forces of these two companies make a difference in the world of healthcare. Next, after they combine their products giving them a stronger pipeline to the public and private sector of the global healthcare industry will they survive?
Download or read book The global pharmaceutical industry in the 1990s written by Barrie James and published by . This book was released on 1990 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Global Competitiveness in the Pharmaceutical Industry written by Madhu Agrawal and published by CRC Press. This book was released on 1999-09-03 with total page 220 pages. Available in PDF, EPUB and Kindle. Book excerpt: Examine the global pharmaceutical industry and the effect of national, regulatory, economic, and market environments on the competitiveness of the industry! This unique book is the only empirical study that examines the effects of the national environment on the competitiveness of a country's pharmaceutical industry. This informative book explores such topics as the types of comparative advantages that firms use for developing competitive advantages and what strategic choices firms should make when collaborating with international firms. Public policy implications with respect to the economic environment are also discussed to give you a complete look at the international pharmaceutical industry. Global Competitiveness in the Pharmaceutical Industry recognizes pharmaceutical industries as being of great social and public importance to all countries, since so many life saving drugs have emerged from pharmaceutical laboratories over the past four decades. By helping to combat many fatal diseases and eradicate others, drug producers have helped to positively alter mortality patterns in many parts of the world, thus making companies compete to provide many important medicines. The unique research presented in this book examines the determinants of global competitive advantage in the pharmaceutical industry by answering such questions as: Which factors stimulate or inhibit a nation's pharmaceutical industry to be globally innovative? Which factors stimulate or inhibit diffusion of pharmaceutical innovations (NECs) into its markets? Are there differences between industrialized and developing countries with respect to factors that affect innovation and global competitiveness in the pharmaceutical industry? Global Competitiveness in the Pharmaceutical Industry makes several theoretical, empirical, and methodological contributions which lead to results and generate important managerial and public policy implications. You will find a comprehensive overview of the nature of global competition in the pharmaceutical industry and its evolution in the post World War II period. Global Competitiveness in the Pharmaceutical Industry provides you with an in-depth understanding of the dynamics and importance of the global pharmaceutical market.
Download or read book The Global Politics of Pharmaceutical Monopoly Power written by Ellen F. M. 't Hoen and published by . This book was released on 2009 with total page 136 pages. Available in PDF, EPUB and Kindle. Book excerpt: In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.
Download or read book The Influence of the Pharmaceutical Industry written by Great Britain: Parliament: House of Commons: Health Committee and published by The Stationery Office. This book was released on 2005-04-26 with total page 556 pages. Available in PDF, EPUB and Kindle. Book excerpt: Incorporating HC 1030-i to iii.
Download or read book The Changing Economics of Medical Technology written by Institute of Medicine and published by National Academies Press. This book was released on 1991-02-01 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
